Teva Pharmaceutical Announces New Study Demonstrated Significant Reduction in Annualized Relapse Rate and Halting of Disability Progression in MS Patients Switching To Copaxone

Teva Pharmaceutical Industries Ltd. TEVA today announced preliminary data from two studies, Coptimize and QualiCop. The global Coptimize study, which followed 688 patients from 19 countries, demonstrated that patients who switched to Copaxone from other approved disease modifying therapies experienced a significant reduction of 61 percent in ARR. Switching to Copaxone® treatment also halted the progression of disability of patients in the trial. A majority of patients reported better overall wellbeing and less adverse events after switching to Copaxone.